Reaction
Fulminant Type 1 Diabetes Mellitus reporting signals
As of the last recalculation, Fulminant Type 1 Diabetes Mellitus appears in 1,007 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 312.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 597 | 312.0 | 314.0 |
| Ipilimumab | 213 | 129.1 | 129.7 |
| Pembrolizumab | 147 | 33.6 | 33.7 |
| Atezolizumab | 56 | 31.5 | 31.5 |
| Durvalumab | 29 | 30.3 | 30.4 |
| Febuxostat Tablets 40 Mg | 11 | 22.6 | 22.6 |
| Febuxostat Tablets 80 Mg | 11 | 22.6 | 22.6 |
| Lenvatinib | 29 | 18.8 | 18.8 |
| Dexamethasone Sodium Phosphate | 9 | 18.5 | 18.5 |
| Oxaliplatin | 61 | 18.0 | 18.0 |
| Fexofenadine Hcl | 8 | 18.0 | 18.0 |
| Magnesium Oxide | 33 | 16.8 | 16.8 |
| Lubiprostone | 7 | 15.4 | 15.4 |
| Febuxostat | 11 | 13.7 | 13.7 |
| Pemetrexed | 14 | 13.7 | 13.7 |
| Paclitaxel (Aibumin-Bound) | 47 | 12.3 | 12.4 |
| Paclitaxel | 55 | 12.1 | 12.1 |
| Carboplatin | 61 | 10.5 | 10.5 |
| Pemetrexed Disodium | 19 | 10.5 | 10.5 |